PCSK9 and atherosclerosis: Those at risk for ASCVD should receive statin-based care, with attention to LDL-C (as well as non-HDL-C and/or apoB), with pharmacotherapy known to reduce ASCVD risk including ezetimibe, proprotein convertase subtilisin-kexin 9 monoclonal antibodies (PCSK9 mAb), and/or a high dose icosapent ethyl esters according to the level of risk and lipid/lipoprotein response.